From scarring to skin bleachig and more, this issue of Dermatology Times focuses on pigmentary disorders. We feature talks from this year's Skin of Color Seminar Series meeting, but also feature clinical pearls for calming inflammation and we include a supplement issue featuring advances for the treatment and management of acne.
Eczema, food allergy, and asthma independently and cumulatively increase the risk for eosinophilic esophagitis (EoE).
A novel picosecond/nanosecond 670 nm wavelength is safe and effective for the treatment of benign pigmented lesions.
Despite the popularity of fractional ablative resurfacing, full-field erbium (2,940 nm) resurfacing still plays an important role, says Joel L. Cohen, M.D., a dermatologist in Greenwood Village, Colorado.
Pediatric melanomas are often misdiagnosed by physicians. Adolescents have a more aggressive disease course than children and are treated with adult protocols leading to chronic morbidity.
Oral propranolol may be safe for infants with uncomplicated hemangiomas, but for those with underlying health conditions, it may not always be the treatment of choice.
Efficacy and safety outcomes of clinical trials involving biologic psoriasis drugs overstate these drugs' real-world utility, shows a JAMA Dermatology study.
The TNF alpha inhibitor certolizumab pegol has achieved the highest response rates seen in phase three trials of self-injectable biologics for psoriasis, shows a study published in JAAD.
For some patients with moderate to severe atopic dermatitis, the combination of dupilumab and corticosteroids may be necessary to control flares, a new study shows. Dupilumab is a proven treatment for AD, so where do we go from here? A physician writing in BJD suggests predictive modeling.